Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
173.25
+1.06 (0.62%)
At close: Feb 23, 2026, 4:00 PM EST
173.35
+0.10 (0.06%)
After-hours: Feb 23, 2026, 7:05 PM EST
Jazz Pharmaceuticals Employees
Jazz Pharmaceuticals had 2,800 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
2,800
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$1,484,940
Profits / Employee
-$131,601
Market Cap
10.53B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 2,800 | 0 | - |
| Dec 31, 2023 | 2,800 | 0 | - |
| Dec 31, 2022 | 2,800 | -400 | -12.50% |
| Dec 31, 2021 | 3,200 | 1,260 | 64.95% |
| Dec 31, 2020 | 1,940 | 320 | 19.75% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Bio-Techne | 3,100 |
| BioMarin Pharmaceutical | 3,040 |
| Exelixis | 1,077 |
| Axsome Therapeutics | 816 |
| Arrowhead Pharmaceuticals | 711 |
| ImmunityBio | 673 |
| Madrigal Pharmaceuticals | 528 |
| Avidity Biosciences | 391 |
JAZZ News
- 6 days ago - Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences - PRNewsWire
- 13 days ago - Jazz Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, February 24, 2026 - PRNewsWire
- 5 weeks ago - Jazz Pharmaceuticals plc (JAZZ) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 6 weeks ago - Boehringer Ingelheim announces clinical collaboration with Jazz Pharmaceuticals to advance HER2-targeted therapy in breast cancer - GlobeNewsWire
- 6 weeks ago - Jazz Pharmaceuticals plc (JAZZ) Discusses HERIZON-GEA-01 Phase III Trial Results for Zanidatamab in HER2+ GEA Transcript - Seeking Alpha
- 6 weeks ago - Jazz Pharmaceuticals: A Strong Buy Due To Execution In Oncology - Seeking Alpha
- 6 weeks ago - Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer - PRNewsWire
- 6 weeks ago - Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA Including More Than Two Years Median Overall Survival Benefit - PRNewsWire